CytRx Corporation – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “CytRx Corporation - Product Pipeline Review - 2013” provides data on the CytRx Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CytRx Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from CytRx Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “CytRx Corporation - Product Pipeline Review - 2013” provides data on the CytRx Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CytRx Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from CytRx Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- CytRx Corporation - Brief CytRx Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CytRx Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CytRx Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CytRx Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate CytRx Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CytRx Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CytRx Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CytRx Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas.
CytRx Corporation Snapshot
CytRx Corporation Overview
Key Information
Key Facts
CytRx Corporation – Research and Development Overview
Key Therapeutic Areas
CytRx Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CytRx Corporation – Pipeline Products Glance
CytRx Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CytRx Corporation – Drug Profiles
aldoxorubicin
Product Description
Mechanism of Action
R&D Progress
tamibarotene
Product Description
Mechanism of Action
R&D Progress
tamibarotene
Product Description
Mechanism of Action
R&D Progress
CytRx Corporation – Pipeline Products by Route of Administration
CytRx Corporation – Pipeline Products By Mechanism of Action
CytRx Corporation – Recent Pipeline Updates
CytRx Corporation - Dormant Projects
CytRx Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
INNO-105
INNO-305
CytRx Corporation – Company Statement
CytRx Corporation – Locations And Subsidiaries
Head Office
CytRx Corporation, Recent Developments
CytRx Corporation- Press Release
Feb 28, 2013: CytRx Reaches Patient Enrollment Target In Global Phase IIb Clinical Trial With Tamibarotene As First-line Treatment For Non-Small Cell Lung Cancer
Jan 31, 2013: CytRx Receives Recommendation From Data Safety Monitoring Committee To Complete Global Phase IIb Clinical Trial With Tamibarotene As First-line Treatment For Non-Small Cell Lung Cancer
Jan 28, 2013: CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy
Dec 07, 2010: CytRx Reports INNO-206 Positive Preclinical Study Results In Multiple Myeloma
Dec 01, 2010: CytRx Initiates Phase IIb Clinical Trial With Tamibarotene In Advanced Lung Cancer
May 03, 2010: CytRx's INNO-206 Rapidly Shrinks Human Tumors In Animal Model Of Multiple Myeloma
Jan 06, 2010: CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 For The Treatment Of Advanced Pancreatic Cancer
Financial Deals Landscape
CytRx Corporation, Deals Summary
CytRx Corporation, Pharmaceuticals & Healthcare, Deal Details
Equity Offering
CytRx Files Registration Statement For Public Offering Of Securities For $100 Million
CytRx Completes Public Offering Of Common Stock For $23 Million
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
Asset Transactions
Orphazyme Acquires Molecular Chaperone Assets From CytRx
Acquisition
Adventrx Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Sells Remaining 17% Stake In RXi Pharma For $7 Million
CytRx Acquires INNOVIVE Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
CytRx Corporation, Key Information
CytRx Corporation, Key Facts
CytRx Corporation – Pipeline by Indication, 2013
CytRx Corporation – Pipeline by Stage of Development, 2013
CytRx Corporation – Monotherapy Products in Pipeline, 2013
CytRx Corporation – Phase II, 2013
CytRx Corporation – Phase I, 2013
CytRx Corporation – Pipeline By Route of Administration, 2013
CytRx Corporation – Pipeline Products By Mechanism of Action, 2013
CytRx Corporation – Recent Pipeline Updates, 2013
CytRx Corporation - Dormant Developmental Projects,2013
CytRx Corporation - Discontinued Pipeline Products, 2013
CytRx Corporation, Deals Summary
CytRx Files Registration Statement For Public Offering Of Securities For $100 Million
CytRx Completes Public Offering Of Common Stock For $23 Million
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
Orphazyme Acquires Molecular Chaperone Assets From CytRx
Adventrx Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Sells Remaining 17% Stake In RXi Pharma For $7 Million
CytRx Acquires INNOVIVE Pharma
LIST OF FIGURES
CytRx Corporation – Pipeline by Indication, 2013
CytRx Corporation – Pipeline by Stage of Development, 2013
CytRx Corporation – Monotherapy Products in Pipeline, 2013
CytRx Corporation – Pipeline By Route of Administration, 2013
CytRx Corporation - Pipeline Products By Mechanism of Action, 2013
CytRx Corporation Overview
Key Information
Key Facts
CytRx Corporation – Research and Development Overview
Key Therapeutic Areas
CytRx Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CytRx Corporation – Pipeline Products Glance
CytRx Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CytRx Corporation – Drug Profiles
aldoxorubicin
Product Description
Mechanism of Action
R&D Progress
tamibarotene
Product Description
Mechanism of Action
R&D Progress
tamibarotene
Product Description
Mechanism of Action
R&D Progress
CytRx Corporation – Pipeline Products by Route of Administration
CytRx Corporation – Pipeline Products By Mechanism of Action
CytRx Corporation – Recent Pipeline Updates
CytRx Corporation - Dormant Projects
CytRx Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
INNO-105
INNO-305
CytRx Corporation – Company Statement
CytRx Corporation – Locations And Subsidiaries
Head Office
CytRx Corporation, Recent Developments
CytRx Corporation- Press Release
Feb 28, 2013: CytRx Reaches Patient Enrollment Target In Global Phase IIb Clinical Trial With Tamibarotene As First-line Treatment For Non-Small Cell Lung Cancer
Jan 31, 2013: CytRx Receives Recommendation From Data Safety Monitoring Committee To Complete Global Phase IIb Clinical Trial With Tamibarotene As First-line Treatment For Non-Small Cell Lung Cancer
Jan 28, 2013: CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy
Dec 07, 2010: CytRx Reports INNO-206 Positive Preclinical Study Results In Multiple Myeloma
Dec 01, 2010: CytRx Initiates Phase IIb Clinical Trial With Tamibarotene In Advanced Lung Cancer
May 03, 2010: CytRx's INNO-206 Rapidly Shrinks Human Tumors In Animal Model Of Multiple Myeloma
Jan 06, 2010: CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 For The Treatment Of Advanced Pancreatic Cancer
Financial Deals Landscape
CytRx Corporation, Deals Summary
CytRx Corporation, Pharmaceuticals & Healthcare, Deal Details
Equity Offering
CytRx Files Registration Statement For Public Offering Of Securities For $100 Million
CytRx Completes Public Offering Of Common Stock For $23 Million
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
Asset Transactions
Orphazyme Acquires Molecular Chaperone Assets From CytRx
Acquisition
Adventrx Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Sells Remaining 17% Stake In RXi Pharma For $7 Million
CytRx Acquires INNOVIVE Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
CytRx Corporation, Key Information
CytRx Corporation, Key Facts
CytRx Corporation – Pipeline by Indication, 2013
CytRx Corporation – Pipeline by Stage of Development, 2013
CytRx Corporation – Monotherapy Products in Pipeline, 2013
CytRx Corporation – Phase II, 2013
CytRx Corporation – Phase I, 2013
CytRx Corporation – Pipeline By Route of Administration, 2013
CytRx Corporation – Pipeline Products By Mechanism of Action, 2013
CytRx Corporation – Recent Pipeline Updates, 2013
CytRx Corporation - Dormant Developmental Projects,2013
CytRx Corporation - Discontinued Pipeline Products, 2013
CytRx Corporation, Deals Summary
CytRx Files Registration Statement For Public Offering Of Securities For $100 Million
CytRx Completes Public Offering Of Common Stock For $23 Million
CytRx Completes Public Offering Of Common Stock For $20.4 Million
CytRx Completes Public Offering Of $20 Million
CytRx Completes Private Placement Of $37 Million
Orphazyme Acquires Molecular Chaperone Assets From CytRx
Adventrx Pharma Completes Acquisition Of SynthRx From CytRx
CytRx Sells Remaining 17% Stake In RXi Pharma For $7 Million
CytRx Acquires INNOVIVE Pharma
LIST OF FIGURES
CytRx Corporation – Pipeline by Indication, 2013
CytRx Corporation – Pipeline by Stage of Development, 2013
CytRx Corporation – Monotherapy Products in Pipeline, 2013
CytRx Corporation – Pipeline By Route of Administration, 2013
CytRx Corporation - Pipeline Products By Mechanism of Action, 2013
